B+
Bull case
25%
Probability
Target price
$25.00
Analysis reference price unavailable
Analysis 2026-05-16 · RankAlpha Sentiment Codex
DOCS
DoximityDNYSE / Health Care Equipment & Services
Last Price
Quote time unavailable
Current thesis
The primary source still shows a real franchise: FY26 revenue grew 13%, operating cash flow grew 19%, free cash flow grew 19%, and platform engagement hit new highs with over 800,000 workflow-tool prescribers and nearly half using clinical AI in Q4 [#8-K-2026-05-13]. If the FY27 guide proves conservative, the reset could create room for positive revisions.
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.8.
What can break
Competitive risk: analyst commentary flagged growing overlap with AI-native tools and larger healthcare software platforms such as Veeva-style workflows.
Momentum
95
Value
56
Sentiment
22
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $20.50 · Bull $25.00 · Bear $14.50Analysis 2026-05-16; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-23 • Vendor: Data Vendor v1
Scores
As of 2026-10-23 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-16 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-23
Investment thesis
As of 2026-10-23
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-23. Definitions
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $31.05
Why
Momentum95 · Δ7d +4.7
Value56 · Δ7d -0.8
Sentiment22 · Δ7d -3.8
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Value remains the lead driver in the composite, 7D delta -0.8.
Contradictions & invalidation
- • Competitive risk: analyst commentary flagged growing overlap with AI-native tools and larger healthcare software platforms such as Veeva-style workflows.
- • Demand visibility risk: post-earnings coverage cited softer digital pharma demand, shorter contract duration, and policy/macro uncertainty affecting customer commitments.
- • The post-print problem is not the quarter itself but the outlook.
Catalyst clock
2026-05-13
Post-earnings guidance reset reframed the story
Lead driver: Value · See fundamentals
Momentum
95
8% active weight
Current posture
7d trendFlat
Δ7d
+4.7
Δ21d
+13.4
Value
56
47% active weight
Current posture
7d trendFlat
Δ7d
-0.8
Δ21d
-1.9
Sentiment
22
45% active weight
Current posture
7d trendSoftening
Δ7d
-3.8
Δ21d
-16.6
Why this grade
Composite grade D. Momentum 94.6 / Value 56.4 / Sentiment 21.9
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-05-16. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$20.50
Analysis reference price unavailable
Analysis 2026-05-16 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$14.50
Analysis reference price unavailable
Analysis 2026-05-16 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-23
Fundamentals (TTM)
As of 2026-10-23
Market Cap
$5.95B
Beta
1.39
Shares Out
178.25M
P/E (TTM)
36.4
P/S (TTM)
13.84
P/FCF (TTM)
27.56
Rev YoY
+7.3%
EPS YoY
-52.0%
Gross Margin
+87.4%
Op Margin
+30.6%
Net Debt
-$738.42M
Current Ratio
6.04
As of 2026-10-23 • Updated nightlySource: Internal modelMethods & Data